Invesco Ltd. vs Teladoc Health Inc — how do they compare? Invesco Ltd. trades at $31.45 (market cap $13.85B), while Teladoc Health Inc trades at $6.67 (market cap $1.24B). The key difference: Invesco Ltd. is far larger — about 11.2× Teladoc Health Inc's market cap, and Invesco Ltd. pays a 2.74% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| IVZ | TDOC | |
|---|---|---|
Market Cap | $13.85B | $1.24B |
Sector | Financials | Health |
52-Week High | $32.01 | $9.72 |
52-Week Low | $20.67 | $4.47 |
Enterprise Value | $24.01B | $1.50B |
Dividend Yield | 2.74% | — |
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Teladoc Health (TDOC) trades at $6.62, down 6.5% on the day, reflecting investor concern after a Q2 2026 revenue miss and lowered full-year guidance. The stock is technically bearish with key support at $6, while fundamentals show revenue of $2.53B in 2025 but persistent net losses, with a negative net income margin of -7.13%. Recent news highlights multiple law firm investigations into the company following its guidance cut.
The outlook remains challenging due to weak BetterHelp performance and ongoing losses, though valuation ratios like P/S of 0.49 and EV/EBITDA of 6.96 suggest potential undervaluation. Risks include competitive pressures and legal scrutiny, but analyst consensus price target of $8.88 implies upside if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →